JP2024506347A - Ｇｄｃ－９５４５およびイパタセルチブを含む併用療法を使用する乳がんの処置 - Google Patents

Ｇｄｃ－９５４５およびイパタセルチブを含む併用療法を使用する乳がんの処置 Download PDF

Info

Publication number
JP2024506347A
JP2024506347A JP2023548591A JP2023548591A JP2024506347A JP 2024506347 A JP2024506347 A JP 2024506347A JP 2023548591 A JP2023548591 A JP 2023548591A JP 2023548591 A JP2023548591 A JP 2023548591A JP 2024506347 A JP2024506347 A JP 2024506347A
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
combination therapy
patient
gdc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023548591A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022177835A5 (https=
JP2024506347A5 (https=
Inventor
シアラ メトカーフ，
クイ リン，
マルク アントワーヌ ハーフナー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of JP2024506347A publication Critical patent/JP2024506347A/ja
Publication of JPWO2022177835A5 publication Critical patent/JPWO2022177835A5/ja
Publication of JP2024506347A5 publication Critical patent/JP2024506347A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2023548591A 2021-02-16 2022-02-14 Ｇｄｃ－９５４５およびイパタセルチブを含む併用療法を使用する乳がんの処置 Pending JP2024506347A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163149947P 2021-02-16 2021-02-16
US63/149,947 2021-02-16
PCT/US2022/016254 WO2022177835A1 (en) 2021-02-16 2022-02-14 Treatment of breast cancer using combination therapies comprising gdc-9545 and ipatasertib

Publications (3)

Publication Number Publication Date
JP2024506347A true JP2024506347A (ja) 2024-02-13
JPWO2022177835A5 JPWO2022177835A5 (https=) 2025-02-18
JP2024506347A5 JP2024506347A5 (https=) 2025-02-18

Family

ID=80682672

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023548591A Pending JP2024506347A (ja) 2021-02-16 2022-02-14 Ｇｄｃ－９５４５およびイパタセルチブを含む併用療法を使用する乳がんの処置

Country Status (6)

Country Link
US (1) US20230381156A1 (https=)
EP (1) EP4294393A1 (https=)
JP (1) JP2024506347A (https=)
CN (1) CN116847839A (https=)
TW (1) TWI881203B (https=)
WO (1) WO2022177835A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115872996B (zh) * 2023-02-21 2023-05-05 山东绿叶制药有限公司 一种雌激素受体降解剂化合物及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019245974A1 (en) * 2018-06-21 2019-12-26 Genentech, Inc. Solid forms of 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2h-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol and processes for preparing fused tricyclic compounds comprising a substituted phenyl or pyridinyl moiety, including methods of their use
WO2020131765A1 (en) * 2018-12-19 2020-06-25 Genentech, Inc. Treatment of breast cancer using combination therapies comprising an akt inhibitor, a taxane, and a pd-l1 inhibitor

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170362228A1 (en) * 2016-06-16 2017-12-21 Genentech, Inc. TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
CA3109090A1 (en) 2018-08-17 2020-02-20 F. Hoffmann-La Roche Ag Diagnostic and therapeutic methods for the treatment of breast cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019245974A1 (en) * 2018-06-21 2019-12-26 Genentech, Inc. Solid forms of 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2h-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol and processes for preparing fused tricyclic compounds comprising a substituted phenyl or pyridinyl moiety, including methods of their use
WO2020131765A1 (en) * 2018-12-19 2020-06-25 Genentech, Inc. Treatment of breast cancer using combination therapies comprising an akt inhibitor, a taxane, and a pd-l1 inhibitor

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CANCER DISCOV., vol. 7, no. 1, JPN6025051014, 2017, pages 102 - 113, ISSN: 0005754028 *
CLIN. CANCER RES., vol. 19, no. 7, JPN6025051015, 2013, pages 1760 - 1772, ISSN: 0005754029 *

Also Published As

Publication number Publication date
EP4294393A1 (en) 2023-12-27
TWI881203B (zh) 2025-04-21
WO2022177835A1 (en) 2022-08-25
CN116847839A (zh) 2023-10-03
TW202237099A (zh) 2022-10-01
US20230381156A1 (en) 2023-11-30

Similar Documents

Publication Publication Date Title
JP7667132B2 (ja) Ａｔｐ競合性ａｋｔ阻害剤、ｃｄｋ４／６阻害剤、およびフルベストラントを含む併用療法を使用した乳がんの処置
US20240173306A1 (en) Treatment of breast cancer using combination therapies comprising gdc-9545 and a cdk4/6 inhibitor
US20230381155A1 (en) Treatment of breast cancer using combination therapies comprising gdc-9545 and gdc-0077
US20230381156A1 (en) Treatment of breast cancer using combination therapies comprising gdc-9545 and ipatasertib
JP7846700B2 (ja) Ｇｄｃ－９５４５とアベマシクリブ又はリボシクリブとを含む併用療法を使用する乳がんの治療
HK40101825A (zh) 使用包括gdc-9545和依帕他赛的组合疗法治疗乳腺癌
HK40101173A (zh) 使用包括gdc-9545和gdc-0077的组合疗法治疗乳腺癌
HK40098151A (zh) 使用包括gdc-9545以及阿贝西利或者瑞博西尼的组合疗法治疗乳腺癌
HK40084792A (en) Treatment of breast cancer using combination therapies comprising gdc-9545 and a cdk4/6 inhibitor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250207

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250207

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251212

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251216